Clinical Trial Update: A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) [Phase 3]

View source ↗

Summary

A Phase 3 study investigating Baricitinib (LY3009104) to preserve beta cell function in children and adults newly diagnosed with Type 1 diabetes; the trial is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Baricitinib (LY3009104) (Baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus, Type 1 | Phase 3 | Status: RECRUITING